Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ALIOF:US

133.1800 USD 1.7800 1.35%

As of 20:10:00 ET on 05/01/2015.

Snapshot for Actelion Ltd (ALIOF)

Open: 132.4375 Day's Range: 132.4375 - 133.1800 Volume: 782
Previous Close: 131.4000 52wk Range: 93.0000 - 133.1800 1-Yr Rtn: +35.86%

Stock Chart for ALIOF

No chart data available.
  • ALIOF:US 132.8500
  • 1D
  • 1M
  • 1Y
131.4000
Interactive ALIOF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALIOF

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 23.2772
Relative P/E vs. SPX -
Earnings Per Share (CHF) (ttm) -
Est. EPS (CHF) (12/2015) 5.3410
Est. PEG Ratio 2.4187
Market Cap (M USD) 15,199.62
Shares Outstanding (M) 114.13
30 Day Average Volume 480
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.04%
Cash Dividend (CHF) 1.3000
Dividend Ex-Date 05/12/2015
5 Year Dividend Growth -
Next Earnings Announcement 07/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALIOF

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for ALIOF

Actelion Ltd is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for diseases with significant unmet medical needs. The Company focuses in the field of pulmonary arterial hypertension (PAH) with treatments for diseases from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

Jean-Paul ClozelCEO/Co-FounderAndre C MullerExec VP/CFO
Otto SchwarzExec VP/COONicholas FrancoExec VP/Chief Bus Dev Officer
More Company Profile & Key Executives for ALIOF

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil